These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31761398)

  • 1. Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.
    Sun Y; Wang L; Que Y; Zhu H; Yang X; Li D
    Int J Cardiol; 2020 May; 306():163-167. PubMed ID: 31761398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of arsenic trioxide on QT interval prolongation during APL therapy.
    Zhou J; Meng R; Li X; Lu C; Fan S; Yang B
    Chin Med J (Engl); 2003 Nov; 116(11):1764-6. PubMed ID: 14642155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
    Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
    Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H
    Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Barbey JT; Soignet S
    Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety.
    Siu CW; Au WY; Yung C; Kumana CR; Lau CP; Kwong YL; Tse HF
    Blood; 2006 Jul; 108(1):103-6. PubMed ID: 16514059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
    Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S
    Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
    Fox E; Razzouk BI; Widemann BC; Xiao S; O'Brien M; Goodspeed W; Reaman GH; Blaney SM; Murgo AJ; Balis FM; Adamson PC
    Blood; 2008 Jan; 111(2):566-73. PubMed ID: 17959855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QT prolongation: a case of arsenical pericardial and pleural effusion.
    Vizzardi E; Zanini G; Antonioli E; D'Aloia A; Raddino R; Cas LD
    Cardiovasc Toxicol; 2008 Mar; 8(1):41-4. PubMed ID: 18084726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
    Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
    Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
    Ducas RA; Seftel MD; Ducas J; Seifer C
    J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients.
    Wu M; Pang C; Lu S; Hostetter TH; Hai X
    Environ Toxicol Pharmacol; 2023 Jun; 100():104142. PubMed ID: 37146668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolongation of cardiac repolarization by arsenic trioxide.
    Chiang CE; Luk HN; Wang TM; Ding PY
    Blood; 2002 Sep; 100(6):2249-52. PubMed ID: 12200393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk/benefit profile of arsenic trioxide.
    Rust DM; Soignet SL
    Oncologist; 2001; 6 Suppl 2():29-32. PubMed ID: 11331438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
    Naito K; Kobayashi M; Sahara N; Shigeno K; Nakamura S; Shinjo K; Tobita T; Takeshita A; Ohno R; Ohnishi K
    Int J Hematol; 2006 May; 83(4):318-23. PubMed ID: 16757431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
    Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Sahara N; Takeshita A; Satoh H; Terada H; Ohno R
    Leukemia; 2002 Apr; 16(4):617-22. PubMed ID: 11960341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
    Gupta S; Bagel B; Gujral S; Subramanian PG; Khattry N; Menon H; Nair R
    Leuk Lymphoma; 2012 Nov; 53(11):2192-4. PubMed ID: 22452590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of the tetra-arsenic tetra-sulfide (As4S4) on the corrected QT interval in the treatment of acute promyelocytic leukemia].
    Shen JC; Liu KY; Jiang B; Lu XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):359-61. PubMed ID: 15308017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.